Intrathecal application of PD-1 antibody in metastatic solid tumors with leptomeningeal disease

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514068-14-00

Acronym

IT-PD1

Enrollment

Registered

2024-05-24

Start date

2021-10-12

Completion date

Unknown

Last updated

2024-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

leptomeningeal disease

Brief summary

To assess the maximum tolerable dose and safety of intrathecal (IT) PD-1 antibody administration

Detailed description

Overall survival

Interventions

DRUGOPDIVO 10 mg/mL concentrate for solution for infusion.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
To assess the maximum tolerable dose and safety of intrathecal (IT) PD-1 antibody administration	—

Secondary

Measure	Time frame
Overall survival	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026